CMX001 to Prevent Cytomegalovirus Disease in Hematopoietic-Cell Transplantation

2013370 citationsJournal Articlebronze Open Access

Authors

Francisco M. Marty · Brigham and Women's Hospital

Drew J. Winston · University of California, Los Angeles

Scott D. Rowley · Hackensack University Medical Center

Estil Vance · Texas Oncology

Genovefa A. Papanicolaou · Memorial Sloan Kettering Cancer Center

Kathleen M. Mullane · University of Chicago Medical Center

Thomas M. Brundage

Abstract

Treatment with oral CMX001 at a dose of 100 mg twice weekly significantly reduced the incidence of CMV events in recipients of hematopoietic-cell transplants. Diarrhea was dose-limiting in this population at a dose of 200 mg twice weekly. (Funded by Chimerix; CMX001-201 ClinicalTrials.gov number, NCT00942305.).

Topics & Keywords

Cytomegalovirus and herpesvirus research Herpesvirus Infections and Treatments Polyomavirus and related diseases

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 369, Issue 13, pp. 1227-1236

DOI: 10.1056/nejmoa1303688

Field-Weighted Citation Impact: 34.62